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ABSTRACT 
 
The immune system is the responsible for body integrity and prevention of external invasion. On one side,  nanoparticles 
are no triggers that the immune system is prepared to detect, on the other side it is known that foreign bodies, not only 
bacteria, viruses and parasites, but also inorganic matter, can cause various pathologies such as silicosis, asbestosis or 
inflammatory reactions. Therefore, nanoparticles entering the body, after interaction with proteins, will be either 
recognized as self-agents or detected by the immune system, encompassing immunostimulation or immunosuppression 
responses. The nature of these interactions seems to be dictated not specially by the composition of the material but by 
modifications of NP coating (composition, surface charge and structure). Herein, we explore the use of gold 
nanoparticles as substrates to carry multifunctional ligands to manipulate the immune system in a controlled manner, 
from undetection to immunostimulation. Murine bone marrow macrophages can be activated with artificial nanometric 
objects consisting of a gold nanoparticle functionalized with peptides. In the presence of some conjugates, macrophage 
proliferation was stopped and pro-inflammatory cytokines were induced. The biochemical type of response depended on 
the type of conjugated peptide and was correlated with the degree of ordering in the peptide coating. These findings help 
to illustrate the basic requirements involved in medical NP conjugate design to either activate the immune system or hide 
from it, in order to reach their targets before being removed by phagocytes. Additionally, it opens up the possibility to 
modulate the immune response in order to suppress unwanted responses resulting from autoimmunity, or allergy or to 
stimulate protective responses against pathogens.  
1. INTRODUCTION 
 
Despite the remarkable rapidness in the development of strategies for particle synthesis and functionalization as well as 
the further use of these conjugates in biomedical applications, relatively little is still stated about the interaction of 
nanoparticles (NPs) with living systems
1-3
. This is particularly important for the immune system, which is responsible for 
maintaining body integrity and preventing external invasion. NPs are deliberately injected to perform a specific medical 
application, such as fluorescent agents for imaging, drug delivery vehicles or therapeutic agents for hyperthermia 
treatments, or unintentionally incorporated as a consequence of manufacturing processes, combustion or consumer 
products. In this regard, the assessment of the adverse effects that can result from the exposure of the immune system to 
NPs is of vital importance to provide the basis for designing safer, and more efficient biomaterials.  
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The immune system is a collection of mechanisms within an organism to protect it against disease by identifying and 
detecting pathogens. Its main function is the self/non‑self discrimination, therefore detecting a wide variety of agents, 
from viruses to parasites, and distinguishing them from the organism own healthy cells and tissues
4
. Vertebrates are 
endowed with an immune system with two major subdivisions, the innate or non‑specific immune system, which is the 
first line of defense against invading organisms, and the adaptive or specific immune system, acting as a second line of 
defense and providing protection against re-exposure. The immediate response is carried out by the innate immune 
system which is not antigen specific and reacts equally well to a variety of organisms, typically triggering a protective 
inflammatory response within minutes. If the intruding object is not eliminated, the innate immune precedes and 
empowers the adaptive immune response, reacting only with the organism that induced the response.  
Since NPs are no triggers that the immune system is prepared to detect, the innate immune system is supposed to first 
react with NPs. NPs entering the body can be either recognized as self-agents or detected by the immune system, 
encompassing immunostimulation or immunosuppression. responses. The former case represents the major area of 
interest in the area of drug delivery and several camouflaging strategies, based on their functionalization with 
poly(ethylene glycol) (PEG) or other types of polymers, have been reported
5
. Interestingly, although these strategies 
represent effective ways to avoid primary immune recognition, an associated problem is the formation of PEG-specific 
antibodies, which leads to altered pharmacokinetics of NPs after successive exposures
6,7
, something shown in the case of  
liposomes. On the other hand, when detected, the immunostimulation potential of NPs can significantly contribute to the 
development of improved vaccine formulations (using the NPs as vaccine adjuvants)
8
. The nature of these interactions 
seems to be dictated not only by the composition of the material but also by the morphology, surface chemistry and 
aggregation state of the colloidal NPs. Thus, previously reported studies show that modifications of NP coating 
(composition, surface charge and structure) modulates the immune response. In fact, the immune system is known to 
response to inorganic particulate material as in the case of asbestosis and silicosis. However, in those cases the particles 
are of few microns or larger beyond the limits of frustrated phagocytosis
9
. These contributions have been widely 
reviewed by Sperling et al.
10
. Additionally, the initial recognition and categorization of NPs by the immune system is an 
essential determining factor for the fate and distribution of these materials inside the body and the interactions of NPs 
with some components of immune system may have a significant impact on their bioavailability and clearance
11
. The 
universal trend is that the smaller particles have a substantially longer lifetime in the blood than the larger particles. For 
instance, 300 nm polymer particles have a typical blood clearance time of a few minutes, while small particles (both 
polymeric and inorganic) of 10-20 nm may have a lifetime in the blood from a few hours to several days
12,13
. Moreover, 
the change of particle size from 240 to 80 nm showed an extension of the half-life of the particles in mice and a drug in it 
(TNFR) by 24-fold from 28.2 min to 11.33 h
14
. 
In this context, we explore the use of Au NPs as substrates to carry multifunctional ligands to manipulate the immune 
system in a controlled manner. Thus, the main goals in this work are to study the conditions by which it is possible (i) to 
modulate the response of the immune system (vaccination, rejection, autoimmunity, allergies, and cancer) and (ii) to 
camouflage the conjugates from the immune system while trying to reach their target (when used as drug delivery 
vehicles or contrast agents). We show how murine bone marrow macrophages were able to recognize peptidic conjugates 
of Au NPs, while peptides or Au NPs alone were not recognized. Consequently, in the presence of conjugates, 
macrophage proliferation was stopped and pro-inflammatory cytokines such as TNF-α  IL-1β  a d IL-6, as well as nitric 
oxide synthase (NOS2) were induced. Furthermore, macrophage activation by Au NPs conjugated to different peptides 
appeared to be rather independent of peptide length and polarity, but dependent on peptide pattern at the NP surface. 
Additionally, the biochemical type of response also depended on the type of conjugated peptide and could be correlated 
with the degree of ordering in the peptide coating. These findings help to illustrate the basic requirements involved in 
medical NP conjugate design to either activate the immune system or hide from it in order to reach their targets before 
being removed by phagocytes. Additionally, it opens up the possibility to modulate the immune response in order to 
suppress unwanted responses resulting from autoimmunity, or allergy or to stimulate protective responses against 
pathogens. Furthermore, the control of the activation of the innate immune system could open the possibility to design a 
new generation of artificial adjuvants and antigen delivery systems for vaccination.  
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2. MATERIALS AND METHODS 
 
2.1 Chemicals 
All chemicals used were of highest available purity, and were supplied by Merck, Sigma-Aldrich, Fluka. The Millipore 
water had a resista ce of 18.2 MΩ cm. Recombi a t M-CSF (1200 U/mL 10 ng/mL) was obtained from R&D Systems 
Inc. (Minneapolis, MN), and alternatively, we used L-cell conditioned medium as the source of M-CSF. All reagents 
were prepared fo  owi g the ma ufacturer’s recomme datio s. 
2.2 Techniques  
UV−visib e spectra were acquired with a  himad u UV-2400 spectrophotometer. Dynamic light scattering (DLS) 
measures were made with a Malvern ZetaSizer Nano ZS instrument operating at a light source wavelength of 532 nm 
and a fixed scattering angle of 173°. Zeta potential was determined using a Malvern ZetaSizer analyzer. These 
measurements were carried out using a control pH of 7.0. Transmission electron microscopy images were recorded with 
a JEOL 1010 microscope which operates at 80 kV. Real time-PCR was carried out with 2X SYBR Green PCR Master 
Mix using the ABI Prism 7900 detection system (Applied Biosystems, Foster City, CA). 
2.3 Synthetic Procedures 
Gold nanoparticles of 10 nm to 200 nm in diameter were synthesized following previously developed strategies 
15-17
. In 
detail, a solution of sodium citrate 2.2 mM in Milli-Q water (150 mL) was heated to reflux with a heating mantel in a 
250 mL three-necked round-bottom flask for 15 min under vigorous stirring. After boiling had commenced, 1 mL of 
HAuCl4 25 mM was injected. The resulting particles were stabilized with negatively charged citrate ions and were thus 
well suspended. Immediately after the synthesis of the Au seeds and in the same reaction vessel, the reaction was cooled 
until the temperature of the solution reached 90 °C. Then, 1 mL of a HAuCl4 solution (25 mM) was injected. After 30 
min, the reaction was finished. This process was repeated twice. After that, the sample was diluted by extracting 55 mL 
of sample and adding 53 mL of MQ water and 2 mL of 60 mM sodium citrate. This solution was then used as a seed 
solution, and the process was repeated again. By changing the volume extracted in each growth step, it is possible to tune 
the seed particle concentration. 
CLPFFD and isomers were synthesized by solid-phase synthesis using the 9-fluorenylmethoxycarbonyl/tert-butyl 
(Fmoc/tBu) strategy and a Multiple Advanced Chemtech 496 Synthesizer. Rink amide resi   Nα-Fmoc-protected amino 
acids (4 equiv)/HBTU(4 equiv)/HOBt(4 equiv) and DIEA(8 equiv) were used. Fmoc protecting group was cleaved by 
treatment with a solution of 25% piperidine in DMF. Peptides were cleaved from the resin by treatment with 95% TFA, 
2.5% TIS, 2.5% water for 2 h. C(VRLPPP)3, was synthesized manually by solid-phase synthesis using the 9-
fluorenylmethoxycarbonyl/tert-butyl (Fmoc/tBu) strategy. 2-Ch orotrity  resi   Nα-Fmoc-protected amino acids (2 
equiv)/TBTU(2 equiv) and DIEA(6 equiv) were used. As a protecting group for the Arg side-chain, 2,2,4,6,7-
pentamethyldihydrobenzofurane-5-sulfonyl (Pbf) was used. The Fmoc protecting group was cleaved by treatment with a 
solution of 20% piperidine in DMF (2 × 10 min). To incorporate the Fmoc-Arg(Pbf)-OH, the TBTU was replaced by 
PyBOP (2 equiv). C-SAP was cleaved from the resin by treatment with 95% TFA, 2.5% TIS, 2.5% water for 1 h 30 min. 
All peptides were purified by semipreparative RP-HPLC and characterized by MALDI-TOF mass spectrometry. 
2.4 Gold Nanoparticles Conjugation 
A  aqueous peptide so utio  (20 μM) was added to the Au NP so utio  a d stirred for 30 mi  at room temperature. 
Excess peptides were removed from the NPs by dialysis (3500 or 6-8000 MWCO depending on the sequence, Spectrum 
Lab, Rancho Dominguez, CA) for 3 days at room temperature. BSA degradation and reduction: BSA (Cohn Fraction V, 
Fluka) was degraded with trypsin (trypsin from bovine pancreas, E.C. 3.4.21.4, Roche). 
B A was i cubated at 37 °C disso ved i   ris·HC  100 mM at 150 μM  a d trypsi  was added at the final concentration 
of 35.8 mg/mL (3.94 U/mL, U: Chromozym Try as a substrate). After 24 h at 37 °C, tris(2-carboxyethyl) phosphine 
hydrochloride (TCEP) obtained from Fluka at a final concentration of 10.5 mM was added and incubated during 1 h 30 
min at room temperature to reduce disulfide bonds. This solution was conjugated to Au Np with the same protocol used 
for the different peptides. 
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2.5 Cell Culture 
Primary cu tures of bo e-marrow-derived macrophages were obtai ed from BALB c mice (Har a  Ib rica  Barce o a  
Spain) and cultured as previously described during 6 days at 37 °C and 5% CO2 incubators in DMEM (BioWhittaker-
Cambrex, Emerainville, France), supplemented with 20% FCS and 30% L-cell conditioned media. The use of animals 
was approved by the Animal Research Committee of the University of Barcelona (No. 2523). To render macrophages 
quiescent, they were deprived of M-CSF for 18 h before stimulation. 
2.6 Proliferation Assay 
After 24 h of treatment, cells were pulsed with 3H-d hd (1 μCi mL) (Amersham Pharmacia Biotech  Piscataway  NJ) for 
6 h as previously described. After stimulation, cells were fixed with MeOH 70% at 4 °C overnight. Then, three washes 
of TCA 10% were performed and cells were lysed with NaOH plus SDS. 3H incorporation was mesured by standard 
liquid scintillation. Each point was performed in triplicate and the results were expressed as the mean ± SD. 
2.7 Real-Time PCR 
RNA Extraction and Real-Time PCR: Total RNA was extracted with the RNA Kit EZ-RNA (Biological Industries, 
Kibbutz beit hemeek, Israe ) as i dicated. cDNA was obtai ed from 1 μg of tota  RNA usi g M-MLV Reverse 
Transcriptase (Promega, Madison, WI) as described. Primer Express software (Applied Biosystems) was used to design 
primer sequences used for TNF-α  IL-1β  IL-6, and NOS2. Specific primer pairs were CCTTGTTGCCTCCTCTTTT GC 
and TCAGTGATGTAGCGACAGCCTG for TNF-α  CC G G    CC CC  GCC  a d 
GCCTAATGTCCCCTTGAATCAA for IL-1β  CAGAAGGAG GGC AAGGACCA a d ACGCAC  
AGGTTTGCCGAGTAG for IL-6, GCCACCAACAATGGCAACA and GTACCGGATGAGCTGTG AATT for NOS2, 
AC A  GGCAACGAGCGG  C a d AAGGAAGGC GGAAAAGAGCC for β-actin, forward and reverse, 
respectively. Thermal cycling conditions were 94 °C, 30 s; 60 °C, 30 s; 72 °C, 30s for 35 cycles. Each sample was 
analyzed in triplicate. Expression levels were norma i ed to β-actin. Relative values from a representative experiment out 
of two independent experiments are shown. 
2.8 TEM Preparation 
Cells were fixed with a glutaraldehide 2.5% solution in PB 0.1 M for 1 h. After that cells were scraped, centrifuged at 4 
°C, 2500 rpm, 10 min, and washed with PB 0.1 M. After the staining with OsO4 1% for 1 h, cells were dehydrated in 
acetone at 4 °C and infiltered in Spurr epoxy resin. After embedment (60 °C, 48 h), 50 nm ultrathin sections were created 
with an ultramicrothom. Finally cells were stained with uranyl acetate and lead citrate. 
 
3. RESULTS  
 
3.1 Synthesis and Characterization of Gold Nanoparticles: Size and Shape Control.  
Beyond the direct size-effect on immune response, the study of the interactions between Au NPs and immune system 
requires a wide catalog of NPs with controlled size, morphology, structure and composition. Thus, the increase of Au NP 
size (which entails a decrease of the curvature radii) increases the density number of loaded molecules
18
, therefore 
leading to different molecular ordering. As a result, a wide variety of Au NP conjugates, with different order, structure 
and density may be achieved by controlling Au NPs. Additionally, larger Au NPs show faceted crystals displaying flat 
surfaces, edges and corners.  
Au NPs (~3 10
12
 NPs/mL) of ~10 nm in diameter were prepared by injecting an aqueous HAuCl4 precursor solution into 
a boiling solution of sodium citrate (SC). The role of sodium citrate (SC) in the formation and growing mechanism of Au 
NPs was systematically examined, obtaining that oxidation of SC can be induced either by the presence of HAuCl4 or by 
its thermal decomposition under air 
16
. As a result, it was proved that it is possible to increase the oxidation rate of SC by 
exchanging the order of reagent addition, which leads to a better control of Au NPs size and morphology in comparison 
to standard Turkevich approach. Size and morphology control of larger particles was achieved by developing a 
kinetically-controlled seeded-growth method in which the above synthesized 10 nm Au NPs were used as seeds
15
. The 
method focuses on the inhibition of secondary nucleation during the homogeneous growth process, while keeping the 
solution supersaturated enough to achieve the growth of seed particles via the catalyzed reduction of Au
3+
 by sodium 
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citrate. The success of the method relies on the kinetic control of the growth process by adjusting reaction conditions, in 
particular, i) temperature, ii) pH level, and iii) seed concentration. As the kinetics of the gold reduction significantly 
depends on the temperature
15
, it is expected the decrease of the nucleation rate at lower temperatures (90°C), which leads 
to more favorable conditions for particle growth (kinetic control). Another important aspect is the pH of the solution, 
which has to be maintained around 7 during whole growth process
19
 to control the reactivity of the Au
3+
 species and 
avoid the protonation of citrate. This condition was achieved by adjusting the amount of SC on each growth step, using it 
as pH buffer. Finally, secondary nucleation of particles was avoided by both decreasing the temperature of the solution 
and carefully controlling the ratio between gold precursor added and concentration of seed particles. The control of all of 
these parameters allows not only the synthesis of monodisperse Au NPs with diameters ranging from 10 to 200 nm but 
also provides key aspects, identifying and explaining the important synthetic variables that must be controlled in order to 
control the Au NP morphology.  
Figure 1-A shows morphological characterization of resultant Au NPs obtained by Transmission Electron Microscopy 
(TEM), where it can be seen how the final size of the particles increases (from 10 to 150) as the number of growth steps 
increases (from 1 to 13). As each growth step withstand the dilution of previously obtained particles, the concentration of 
the colloidal solutions depends on particle size ranging from ~3 10
12
 NP/mL (10 nm) to ~8 10
9
 NP/mL (150 nm). It is 
important to note here that, although the particles are rather faceted and thus not perfectly spherical, the growth is very 
uniform, without the formation of elongated particles or a second population of smaller particles. A detained description 
of the process has been previously published by our group
15
. 
 
 
Figure 1.Kinetically-controlled  Seeded-growth of citrate-stabilized gold nanoparticles  the seed solution. (A) 
Transmission electron microscopy images of Au NPs obtained after different growth steps. From left to right: ~ 18 nm 
(1st GS); ~ 30 nm (3rd GS), ~ 42 nm (5th GS); ~ 70 nm (6th GS); ~ 110 nm (11th GS) and ~ 150 nm (13th GS) . (B) 
Hidrodynamic size distribution of synthesized Au NPs measured by Dynamic Light Scattering. Mean size increases from 
~8.5 nm (seed particles) up to 165 nm after 13th growth steps.(C) UV–vis spectra of Au colloids obtained after different 
growth steps. All spectra all normalized at 400 nm to facilitate comparison. 
 
To further corroborate sample uniformity, size distribution of colloidal solutions was studied by Dynamic Light 
Scattering (DLS). Figure 1-B shows DLS distributions of Au NPs synthesized after different growth steps, obtaining that 
hidrodynamic size increases from ~8.5 nm, in the case of seed particles, up to ~165 nm, after 13 growth steps. Moreover, 
distributions are monomodal, which indicates that neither secondary nucleation nor aggregation of Au NPs occurred 
during the growth process. The optical properties of Au NP solutions were measured by UV-Vis spectroscopy (Fig. 1-C). 
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An initial red-shift, from 518.5 to 556 nm of the surface plasmon resonant (SPR) band, indicative of the mean size 
distribution of the colloidal gold solution, was obtained as the size of Au NPs increased from ~ 8.5 nm to ~ 95 nm . 
Further increase of Au NP size leads to a broadening of  the main dipolar resonance band, peaking at ~ 575 nm for Au 
NPs with an average diameter of ~110 nm. Interestingly, above 120 nm, the single band is accompanied by a shoulder at 
lower wavelengths, corresponding to a quadrupolar resonance, placed at ~540 nm for 150 nm Au NPs
20
. These 
experimental absorbance data are in fully agreement with performed calculations based on the standard Mie theory of 
spherical particles
15
.  
3.2 Functionalization of Gold Nanoparticles with Peptides 
As a model for our work, four biomedical significant peptides were conjugated to ~ 10 nm Au NPs: i) Amyloid Growth 
Inhibitor peptide –CLPFFD‑NH2–  comprisi g ami o acids 11 to 16 from the Aβ1‑42 protein that recognize a particular 
hydrophobic domai  of the β‑sheet structure21 and ii) Sweet Arrow Peptide –C(VRLPPP)3–, a non‑toxic 
cell‑penetrating peptide intended for intracellular drug delivery22 and iii) two isomers of CLPFFD‑NH2 peptide, 
(CLPDFF‑NH2 and CDLPFF‑NH2). All the peptides used in our studies present a thiol group in the side chain of the 
N‑terminal cysteine (C) which is able to make a covalent bond to the gold surface23. This interaction may be additive to 
that of the N‑terminal primary amine, since amino groups are also known to have a strong interaction with gold 
surfaces
24
. Moreover, it has been shown that the presence of a positively charged amino group in the vicinity of the thiol 
significantly accelerates the adsorption kinetics of thiols onto citrate‑stabilized Au NPs25. The isoelectric point of 
aminoacids and peptides was studied (Figure 2), obtaining that, at phisiological pH, CLPFFD-NH2, CLPDFF‑NH2 and 
CDLPFF‑NH2 presents one negative charge while C(VRLPPP)3‑COOH presents three positives charges. In these cases, 
when the peptide is linear and the terminal aminoacid is highly hydrophilic, water is excluded and a dense 
self‑assembled monolayer is formed at Au NP surface leading to homogeneous conjugates.  
 
Figure 2. Amino acid (Left) and peptide (Right) charge as a function of the pH of the solution. 
 
As conjugation of one peptide generates a homogenous distribution of peptides onto Au NP surface, we attempt to 
produce heterogeneous Au NP conjugates. Thus, two peptides of different size, C-LPFFD-NH2 and C-(VRLPPP)3-
COOH, or three peptides of different polarity, C-LPFFD-NH2, C-LPDFF-NH2, and C-DLPFF-NH2, were coupled to Au 
NP as their mixtures (AuNP-2PEP, AuNP-3PEP, respectively). Bovine Serum Albumin (BSA) fragments and Fetal Calf 
Serum (FCS) proteins, which are present on cell culture media (FCS enriched DMEM, [FCS:DMEM]=1:10), were also 
conjugated to the Au NPs as controls of heterogeneous conjugates.  
The conjugation process was performed incubating Au NPs with an excess of the N‑termi a  cystei e peptide (20 μM) 
in an aqueous solution for 30 min. The conjugation was carried out in the presence of an excess of peptide in order to 
ensure full coverage of Au NPs, obtaining therefore an homogeneous conjugation. In order to remove the excess of 
unbound peptide, all samples were purified by dialysis. Conjugates were characterized by UV‑Vis spectroscopy, 
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ζ‑Potential and Dynamic Light Scattering. Citrate‑stabilized Au NPs are stable in water and display a characteristic UV-
Vis absorption spectrum with a plasmon band peaking at ~518 nm. The absorption spectrum is sensitive to Au NP 
environment and an observable red‑shift of about 8‑10 nm can be observed once peptides, CLPFFD‑NH2 and 
C(VRLPPP)3‑COOH, are attached. The shift occurs in a few seconds, suggesting that conjugation process is fast, and 
spectra are then stable for weeks. Peptide‑co jugatio  process was a so mo itori ed by DL  a d ζ‑Potential 
measurements. The increases in the hydrodynamic size of the NPs as well as drop in the surface charge once the peptides 
are conjugated to Au NPs, confirm the conjugation process
8,26
. Similarly, the conjugation of Au NPs to CLPDFF‑NH2 
and CDLPFF‑NH2, which contain the same amino acids as CLPFFD albeit in a different sequence, was followed by 
UVVis spectroscopy  DL  a d ζ‑potential measurements. In this case, SPR red‑shifts from 518 nm (Au NPs) to 526 nm 
(AuNP‑CDLPFF‑NH2) and to 524.5 nm (AuNP‑CLPDFF‑NH2) were observed and DLS measurements showed an 
increase of the hydrodynamic diameter of approximately 5 nm, once CLPDFF‑NH2 and CDLPFF‑NH2 are attached to 
Au NP surface. ζ‑potential results suggest not only the success of the conjugation process but also that these conjugates 
are stable by mainly by steric means. 
 
Figure 3. Effect of ionic strength on the stability of citrate‑stabilized Au NPs and CLPFFD-conjugated Au NPs. 
UV−Vis absorptio  spectra of Au NPs (A) a d CLPFFD-conjugated Au NPs (B) at pH 7 in the presence of an added 
amount of NaCl. and Aggregation parameters as a function of [NaCl]. The quantities refer to concentrations in the final 
solution. The decrease of the overall spectra in the case of CLPFFD-conjugated Au NPs is a consequence of the sample 
dilution that took place when the NaCl solution was added.  
 
Colloidal particles have an inherent tendency to aggregate due to attractive van der Waals (vdW) forces. In order to 
stabilize the particles against these attractive forces, it is necessary to introduce a repulsive inter‑particle force, either by 
electrostatic or a steric means. In the case of Au NPs, typically synthesized following a sodium-citrate reduction ruction 
reaction, their electrostatic stabilization arises from a mutual repulsion that occurs as a result of the negative surface of 
the citrate Au NP coating. Oppositely, in the case of Au NPs conjugates the stabilization mechanism can be provided 
either by electrostatic, steric or electro‑steric interaction. Steric interactions of a molecule with a surface layer can 
Proc. of SPIE Vol. 8232  823217-7
Downloaded From: http://proceedings.spiedigitallibrary.org/ on 11/23/2013 Terms of Use: http://spiedl.org/terms
30
a
' 20
10
0
[b AuNP-CDLPFF- NH
? Q 3
( c'-
0-10
0
I-
400" Q4''
0- .-
0
E
2
0-
0-'> 0-
30
0 30
0._a 0-
20 20
10 10
0 0
I-
0
30
0_.
0-0. 20
10
30
20
10
-1--
-1--
3o
0_..
' 2
10-
0
I-
A AuNP-CLPFFD- NH,
E AuNP-BSA
B CAuNP-C(VRLPPP)-COOH AuNP-CLPDFF- NH
 
 
 
 
 
provide greater stability to a colloid than pure electrostatic interactions, since the latter is very sensitive to the pH and the 
ionic strength of the solution
27
.  
Almost for any application, specially biomedicine, the colloidal stability is a necessity. In order to evaluate the 
stabilization mechanism and robustness of Au NP and their conjugates, we studied the aggregation rate of the colloidal 
solution against changes in the ionic strength of the medium, by monitoring the absorption spectra of Au NPs.  It is 
stated that aggregation processes are concomitant with a red‑shift and broadening of SPR band, due to dipole coupling 
between the plasmons of neighboring particles
28,29
. In fact, this aggregation can be quantified by the increase of the 
aggregation parameter
30
, which measures the variation of the integrated absorbance between 600 and 700 nm
30-32
. Figure 
3 shows a set of UV‑Vis spectra of citrate‑stabilized Au NPs and peptide‑conjugated Au NPs at various ionic strengths 
values taken 15 min after the addition of different amounts of sodium chloride (NaCl), where it can be seen how citrate-
stabilized Au NPs agglomerate more and more as the amount of NaCl increases. On the contrary, no virtual changes in 
the position of the SPR can be detected in the case of peptide-conjugated Au NPs. From these results can be concluded 
that the stability of Au NPs conjugates is determined by the stabilization mechanism. Thus, electrically stabilized citrate-
coated Au NPs, are prompt to precipitate by changing the ionis strength of the medium while Au NPs conjugates, 
stabilized by the interactions of molecules side chains or domain, are stable in a broad range of ionic strengths and pH. 
 
3.3 Addressing The Immune System: Macrophages Response towards Peptide‑Conjugated Gold Nanoparticles 
The ability of Au NP and peptidic conjugates to activate the immune system was tested using mice bone marrow 
macrophages as an in vitro model of primary culture of macrophages 
33
. Macrophage proliferation is a well established 
method to verify macrophage activation. Thus, in vitro exposition of macrophages to pathogens and microbe substances 
involves a blockage of proliferation and the acquisition of effector functions
34,35
 producing pro‑inflammatory cytokines, 
such as TNF‑α  IL‑β a d IL‑6 as well as the induction of nitric oxide synthase (NOS2)36.  
 
Figure 4. Macrophage thymidine incorporation assay of Au NP, peptides and conjugates. A) AuNP-CLPFFD-NH2 and 
controls, B) AuNP-C(VRLPPP)3-COOH and controls, C) AuNP-CLPDFF-NH2 and controls, D) AuNP-CDLPFF-NH2 
and control, E) AuNP-BSA and controls and F) AuNP-2PEP / AuNP-3PEP and controls. Resting macrophages were 
stimulated with 1200 U/ml of M‑C F i  the prese ce of the i dicated substa ces (1μM). After 24 hours  thymidi e 
incorporation was measured. Similar results were found in all cases, the peptide‑conjugated Au NPs inhibited the 
macrophage proliferation while the peptides, Au NPs or AuNP-BSA conjugates did not.  
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The potential pro‑inflammatory response of macrophages towards Au NPs conjugates and controls were studied 
analyzing both cytokines production and macrophage proliferation. Macrophage proliferation was assessed by 
radioactive thymidine incorporation. Results plotted in Figure 4 indicate that macrophage proliferation was not affected 
either by citrate-stabilized Au NP or free peptides whereas the corresponding conjugates completely blocked 
proliferation in a dose dependent manner (Fig. 4A-D). Interestingly, the mixture of two peptides of different size (AuNP-
2PEP) or three peptides of different polarity (AuNP-3PEP) managed to block macrophage proliferation (Fig. 4F). Since 
no methodology was available to assess peptide homogeneity on the Au NP surface, we were unable to discern the 
resulting degree of disorganization. Furthermore, homogeneity could be maintained since conjugation kinetics for each 
peptide are likely to be different, thereby leading to ordered peptide domains on the surface of the Au NP. In this regard, 
several reports have shown how different molecules segregate and form defined domains on the surface of NPs
37,38
. On 
the contrary, Au NPs functionalized with BSA fragments were not able to block macrophage proliferation (Fig. 4E). 
Moreover, the simultaneous addition of citrate‑stabilized Au NP and CLPFFD‑NH2 to the cell culture did not block 
macrophage proliferation, suggesting that self‑conjugation has not occurred because the ability of Au NP to attach to 
CLPFFD‑NH2 is quenched by proteins present in the medium
39,40
. In this context, blockage of macrophage proliferation 
seems to be, to some extent, independent on peptide size, charge and composition, but not on coating order.  
The potential pro‑inflammatory response of macrophages to Au NP conjugates and controls was studied by analyzing 
the induction of cytokines (TNF‑α  IL‑β a d IL‑6) as well as nitric oxide synthase (NOS2). LPS was used at subsaturant 
concentrations as a positive control. Accordingly with proliferation arrest, results showed in Figure 5 prove that neither 
peptides nor citrate‑stabilized Au NPs activated any pro‑inflammatory response since both the cytokines and NOS2 
levels were similar to the untreated starved control. However, an exacerbated cytokine and nitric oxide synthase 
induction was observed in the case of peptide‑conjugated Au NPs, indicating a classical macrophage pro-inflammatory 
response. 
 
 
Figure 5. Peptides conjugated Au NPs induced a pro‑inflammatory response in macrophages as can be measured by 
Real Time PCR. (A) CLPFFD‑NH2 and their conjugates, (B) CLPDFF‑NH2 and their conjugates and (C) 
(VRLPPP)3‑COOH and their conjugates. mRNA levels of TNF‑α  IL‑1β  IL‑6 and NOS2 are measured in relation to 
β‑actin of macrophages stimu ated for 6 hours with LP  (10  g m ) or with the i dicated substa ces (1 μM) i  the 
presence of M‑CSF. 
 
To verify that conjugate effects on macrophage proliferation were specific and not a reflection of cell death, apoptosis 
assays were carried out by flow cytometry using Annexin V, as apoptosis marker, in combination with Propidium Iodide 
(PI). Obtained results (data not shown) indicated that none of the substances used in this study compromised cell 
viability, indicating that their effects on proliferation were specific, and suggesting the possibility to induce macrophage 
activation by peptide-conjugated Au NPs, without causing nor altering their cell viability. 
 
Since the blockage of macrophage proliferation and production of cytokines withstand the engagement of phagocytosis, 
we investigated the response and phagocytic activity of macrophages in the presence of Au NP conjugates by TEM. 
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Results depicted in Figure 6 reveal an early (15 min) internalization of peptide-conjugated Au NPs, with the highest 
number of particles internalized after 6 hours, and virtually no particles after 12 hours. Oppositely, the incubation of 
macrophages with non-conjugated Au NPs, or BSA-digest coated Au NPs, revealed no internalization at any time even 
after exhaustive TEM observation.  
 
 
 
Figure 6. Internalization of Au NPs Conjugates observed by Transmission Electron Microscopy (TEM). Representative 
resin‑tomography images revealing internalization of AuNP‑CLPFFD‑NH2 at 15 min, 30 min 1 , 2h and 6 h. 
 
 
4. DISCUSSION AND CONCLUSIONS  
 
4.1 The Effect of the Order in the Peptide Layer 
Recently, it has emerged a clear relationship between protein quaternary structure and higher order organization with 
immunogenicity 
41,42
. Not surprisingly, many viruses exhibit a quasi‑crystalline, highly organized surface that displays a 
regular array of epitopes. In addition, the presentation of an antigen in a highly ordered and repetitive array has prove to 
provoke strong antibody responses in mice, whereas the same antigen presented as a monomer is non‑immunogenic43-46. 
Following these principles it has been observed that the display of peptides, proteins or antigens in an ordered, repetitive 
array (epitope repetition)
43
 are known to induce an enhanced immune response relative to vaccination with the "free" 
protein antigen
4
. This phenomenon is also observed in bacterial surfaces, virus‑like particles (VLPs) and those formed 
on certain viral proteins
47,48
 . Similarly, surface derivation of liposome drug carriers avoid the elimination by 
macrophages (mainly PEGilation) which results in an increase in the blood circulating times
49
. Virus‑like particles 
(VLPs) consist of viral structural proteins that, when over-expressed, spontaneously self‑assemble into particles that are 
antigenically indistinguishable from infectious virus or subviral particles. However, proteins that spontaneously assemble 
to highly repetitive structures, such as VLPs, are rare exceptions. Therefore, epitope‑specific antibody responses may be 
induced by VLPs that contain peptides inserted in their immunodominant regions. However, due to steric problems, the 
size of the peptides capable of being incorporated into VLPs while still permitting capside assembly is rather limited. In 
this sense, NPs have been recently used to electrostatically assist the assembly of brome mosaic virus coating preserving 
virus size, structure and physico‑chemical properties of the native virus50. However, this electrostatic bonding needs an 
excess of conjugating protein in order to be stable and in equilibrium, and may lose stability in vivo.  
Taking into account the above mentioned observations, it can be concluded that the condition for macrophage activation 
is related to the ordered display of peptides, proteins or antigens. Therefore, in our studies we used Au NPs as scaffolds 
to force the self‑assembly of peptides onto Au surface. Moreover, the nature of the peptide chain allows the control of 
packaging degree which determines immune response. In this context, the different immune response obtained for 
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CLPFFD‑NH2 and its isomers CLPDFF‑NH2 and CDLPFF‑NH2 can be explained regarding the different degree of 
conjugation. Amino acids L, P and F are hydrophobic and only the amino acid D presents a negative charge at 
physiological pH, while C is neutral. Thus, the position of the negative charge could be related with the degree of 
conjugation of each peptide on the surface of the Au NP. In the case of CLPFFD‑NH2, when the peptide adopts an 
extended conformation, the D residue localizes away from the gold surface and leads to a higher degree of packing
51
. 
However, when the D residue is near the Au NP surface (AuNP‑CDLPFF‑NH2), a higher repulsion between D residues 
and the exposure of the hydrophobic residues, leads to a lower degree of packing. In the case of CLPDFF‑NH2, an 
intermediate situation occurs. Therefore, the degree of conjugation is AuNP‑CLPFFDNH2 > AuNP‑CLPDFF‑NH2 > 
AuNP‑CDLPFF‑NH2 which is consistent with the observed degree of proliferation arrest (Fig.3). These results were 
confirmed by circular dichroism
52
 and amino acid analisys. Similarly, the blockage of macrophage immune response 
towards AuNP‑ C(VRPPP)3 ‑COOH can be explained in terms of the highly packed layers formed by the C(VRPPP)3 
‑COOH at Au NP surface. In addition, neither the conjugation of Au NPs to BSA fragments nor the non‑specific 
conjugation of Au NPs to media proteins produce activation of macrophage immune response. In this context, it is 
possible to conclude that the condition for the activation of macrophage response is related to the homogeneity of the 
peptide coating layer. In a similar set of experiments, a different immune response was obtained. Using the same 
conjugates on other in vitro differentiated macrophages, the cells apparently detected the Au NPs, but did not elicit any 
proinflamatory reaction (absernce of cytokine induction or proliferation arrest) while showing massive internalization of 
the NPs (Fig.7), suggesting a tolerant response. More analysis on this response will try to correlate structure with degree 
and type of immune response.  
 
 
Figure 7. Massive Internalization of Au NPs Conjugates observed by Transmission Electron Microscopy (TEM). 
Representative resin‑tomography images revealing massive internalization of AuNP‑CLPFFD‑NH2 after 1 hour of 
exposition. 
 
 
4.2 Immunomodulatory Properties of Peptide-funtionalizaed Gold Nanoparticles  
Several conclusions can be drawn from this set of experiments. First, the establishment of a simple set of conditions 
whereby Au NP conjugates can escape from the immune barrier, based upon the design or disorder of a coating structure 
that is very feasible. It is especially important to note that the final biological entity is the one resulting from the 
interaction of the NP conjugates and the proteins in serum medium
53
, which is size and time
39
 and composition 
dependent
40
. Second, the controlled activation of macrophages (and similar effects found in monocytes and dendritic 
cells) may generate adjuvant activity for use in vaccines. The induction of antibodies by prophylactic vaccination against 
infectious diseases has been the most effective medical intervention in human history. The greatest concern regards 
immediate hypersensitivity responses that cause anaphylactic responses. Such responses have been most commonly 
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observed in treatment with bacterial products such as asparaginase, streptokinase, and diphtheria toxin‑conjugated 
molecules. Although inactivated or attenuated vaccines are relatively safe, there is nevertheless a certain probability that 
pathogens might revert to a virulent phenotype in vivo and cause disease, as it is sometimes observed after vaccination 
against polio virus. Consequently, modern vaccines are usually produced recombinantly and do not replicate in the host. 
Unfortunately, isolated soluble components of viruses and other pathogens are often poorly immunogenic in the absence 
of non‑specific inflammatory stimuli54. 
Recombinant vaccines therefore need to be administered together with an adjuvant to enhance immunogenicity. 
However, effective adjuvants are not well tolerated, and only a few of them have the potential to be used in human 
subjects. When looking for alternatives, we observed how the order of NP surface molecules, rather than its chemical 
composition or agglomeration state, is crucial in determining the interaction of NPs with the immune system. Thus, tools 
to improve antigen presentation to the immune system based on the conjugation of inorganic NPs to peptides and the 
rational design of their peptide coating may provide a useful toolkit for vaccinologists and may also serve to change and 
modulate immune response in the fight against allergies, rejection, cancer and autoimmune diseases. In general, it has 
been shown that by providing a TRL ligand with vaccine, the immune response can be both stronger and more profound. 
In particular, Structure Activity Relationship studies (as well as those addressing adjuvant-antigen conjugation) have 
shown that ligand modification can alter the magnitude and character of immune activation, therefore demonstrating that 
structural modification of adjuvants may be therapeutically beneficial. In this scenario, the use of Au NPs conjugates as 
adjuvants may offer several natural advantages: rational design, low toxicity, low-cost and modifiable biodistribution27 
(molecules bound to NPs travel in a different way through the body than those that are unbound). Additionally, Au NPs 
can be loaded with different complementary molecules, or combinations of adjuvants and antigens. These higher-ordered 
structures might facilitate TLR cross-linking and promote the recruitment of one or more additional cofactors or adaptor 
proteins to the signaling complex. Finally, conjugation of antigens to Au NPs can modify the antigen delivery 
mechanism and other immunogenic properties. There is promising evidence that these strategies (i.e., conjugation of 
adjuvants, cofactors, and adaptors with antigens) are effective. All of these advances will provide immunologists with an 
entirely new toolbox with which they can tailor their specific approaches.  
All of this points are relevant for the future development of NP-based medical devices which have to travel to distant 
organs avoiding elimination by the immune system before reaching their target (and avoiding inflammation). In addition 
two other aspects might be considered. First, conjugation protects against systemic degradation
55
. And second, NPs 
change biodistribution of its attached molecules in such a way that they are accumulated in highly phagocyting organs as 
liver, spleen or in the lymph nodes where the adaptive immune response is mainly produced
56
. All in all, the response of 
the immune system towards nanostructured materials is not unique. Thus, some of them may induce a (pro)-
inflammatory response being taken up by phagocytic cells, whereas others seem to reduce these activities reducing the 
ability of these immune cells to fight. Unfortunately, predicting the innate response (in vitro or in vivo) of NPs is still 
difficult to achieve. 
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